A Phase 2 Rollover Protocol of Telaprevir (VX-950) in Combination with Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Enrolled in the Control Group (Group A) of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Who did not Achieve or Maintain an Undetectable HCV RNA Level Through Sustained Viral Response - Rollover Study of Telaprevir (VX-950), Pegasys, and Copegus in Hepatitis C

Vertex Pharmaceuticals Incorporated0 个研究点目标入组 170 人开始时间: 2008年1月3日最近更新: 2012年3月19日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方: Vertex Pharmaceuticals Incorporated
入组人数: 170

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•- Subjects randomized in the Peg-IFN-alfa plus ribavirin control arm (Group A) of Study VX06-950-106, study VX05-950-104 or Study VX05-950-104EU are eligible to participate. Subjects from Study VX06-950-106 must enter the study only after week 24 and within 72 weeks of taking their first dose of study drug in the parent study. subjects from study VX05-950-104 and VX05-950-104EU should enter this study as soon as possible and within 76 weeks of taking their first dose of study drug in the parent study.
•- Subjects must have discontinued treatment in the parent study based on the following criteria: All subjects:
•Viral breakthrough between Week 4 and Week 24. Subjects discontinued study treatment if, on 2 consecutive occasions, the results of HCV RNA testing indicated viral breakthrough. Viral breakthrough is defined as (1) an increase in HCV RNA of >1 log10 compared to the lowest recorded on-treatment value or (2) an HCV RNA level of >100 IU/mL in a subject who had undetectable HCV RNA at a prior time point.
•Week 12 (EVR) Nonresponder, defined as not having achieved an early viral response (EVR, a =2 log10 reduction from baseline in HCV RNA).
•Week 24 Nonresponder, defined as subjects who had detectable HCV RNA at Week 24.
•Week 26 to Week 48 Nonresponder; defined as subjects who had detectable HCV RNA between Weeks 26 and 48.
•Subjects who had detectable HCV RNA during the 24-week post-treatment period. VX06-950-106 subjects only: Week 4 Nonresponder, defined as not having a =1-log10 decrease from baseline in HCV RNA.
•- The screening visit laboratory values must be within the central laboratory reference ranges outlined in the protocol.
•- Subjects must agree to use 2 non-hormonal methods of contraception that are highly effective, with one being a barrier method, (e.g. condom or diaphragm with spermicidal jelly) during telaprevir treatment and 2 months after the last dose of telaprevir. Once treatment with telaprevir is completed, subjects must continue to use 2 efficient methods of contraception for an additional month, (i.e., total of 90 days including 2 non-hormonal methods for the first 2 months of those 90 days), and in line with RBV’s package insert, until 24 weeks after the last dose of RBV have elapsed. Female subjects and female partners of male subjects must use the same precautions. Male subjects must not father a child while on study and for 24 weeks after the last dose of the study medication.
•- Subjects must be willing to refrain from the concomitant use of any medications, substances or foods noted in Section 18 of the protocol.
•- Subjects must be able to read and understand the Informed Consent Form (ICF) and willing to sign the ICF and abide by the study restrictions.
•- Subjects must agree not to participate in other clinical studies for the duration of their participation in this trial.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

排除标准

•- Subjects who discontinued prior Peg-IFN or RBV for adverse events or for any other reason other than failure to respond to therapy and for whom repeated treatment would be inappropriate.
•- Women who are pregnant or breast-feeding.
•- Male partners of women who are pregnant or breast-feeding.
•- Subjects who have taken any of the prohibited medications identified in Section 18 within 30 days of Day 1.

研究者

发起方

Vertex Pharmaceuticals Incorporated

相似试验

进行中（未招募）

不适用

A Phase 2 Rollover Protocol of Telaprevir (VX-950) in Combination with Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Enrolled in the Control Group (Group A) of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Who did not Achieve or Maintain an Undetectable HCV RNA Level Through Sustained Viral Response - Rollover Study of Telaprevir (VX-950), Pegasys, and Copegus in Hepatitis CHepatitis C virus (HCV) infectionMedDRA version: 9.1Level: LLTClassification code 10019744Term: Hepatitis C

EUCTR2006-005123-42-GBVertex Pharmaceuticals Incorporated170

进行中（未招募）

不适用

A Phase 2 Rollover Protocol of Telaprevir (VX-950) in Combination with Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Enrolled in the Control Group (Group A) of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Who did not Achieve or Maintain an Undetectable HCV RNA Level Through Sustained Viral Response - Rollover Study of Telaprevir (VX-950), Pegasys, and Copegus in Hepatitis CHepatitis C Virus InfectionMedDRA version: 9.1Level: LLTClassification code 10019744Term: Hepatitis C

EUCTR2006-005123-42-DEVertex Pharmaceuticals Incorporated170

进行中（未招募）

1 期

EUCTR2006-005123-42-FRVertex Pharmaceuticals Incorporated170

已完成

2 期

A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to TherapyHepatitis C

NCT00535847Vertex Pharmaceuticals Incorporated117

尚未招募

2 期

A Rollover Protocol of Telaprevir (VX-950) in Combination with Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Enrolled in the Control Group (Group A) of Study VX06-950-106 Who did not Achieve or Maintain an Undetectable HCV RNA Level Through Sustained Viral ResponseHepatitis C

NL-OMON30821Vertex Pharmaceuticals5